BC Week In Review | Jun 22, 2018
Clinical News

Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) reported that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with osteoarthritis (OA) of the knee. Cingal comprises a single injection of sodium hyaluronate...
BC Extra | Jun 20, 2018
Clinical News

Anika's Cingal misses in Phase III for osteoarthritis knee pain

Anika Therapeutics Inc. (NASDAQ:ANIK) was off $9.62 (21%) to $36.50 in after-hours trading Tuesday after reporting that Cingal missed the primary endpoint in the Phase III 16-02 trial to treat pain associated with OA of...
BC Week In Review | Jun 20, 2016
Company News

Anika sales and marketing update

Anika launched Cingal in Hungary, Poland, Germany and the Czech Republic to treat pain associated with osteoarthritis. The sodium hyaluronate with triamcinolone hexatonide injection received CE Mark approval in March. Anika declined to provide pricing...
BC Week In Review | Mar 16, 2015
Clinical News

Cingal regulatory update

Anika submitted a PMA in the U.S. for Cingal to treat osteoarthritis (OA) of the knee. Anika also submitted an application for CE Mark approval in the EU at the end of last year. Cingal...
Items per page:
1 - 4 of 4